SLDB
Solid Biosciences Inc. · Healthcare
7.74
0.00%(+0.00)
Close8.96
15.76%(+1.22)
After HoursLast Updated: — ET
52W L: $2.4152W H: $8.72
$7.73
CHG+1.11 (+16.77%)
H$8.67
L$6.40
VOL29M
SLDB (1h)
Solid Biosciences Inc. · Healthcare
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 25th Annual Needham Virtual Healthcare Conference Bo Cumbo, President and CEO, will participate in a virtual fireside chat on Tuesday, April 14, 2026, at 2:15 pm ET.
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) shot up 5.5% on Thursday after Truist Financial upgraded the stock to a strong-buy rating. The stock traded as high as $7.61 and last traded at $7.63. 335,353 shares were traded during mid-day trading, a decline of 75% from the average session volume of 1,345,952
Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eleven have assigned a buy recommendation to the company. The average 12-month
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 -
Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 549,182 shares of the company's stock after selling 174,818 shares during
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
SMITH IAN F
director
3,441 SH @ $0.00
2026-04-02
SMITH IAN F
director
3,441 SH @ $0.00
2026-04-02
PERCEPTIVE ADVISORS LLC
director, 10 percent owner:
8,912,655 SH @ $0.00
2026-03-09
Cumbo Alexander
director, officer: President and CEO
30,031 SH @ $0.00
2026-02-13
Cumbo Alexander
director, officer: President and CEO
16,644 SH @ $5.82
2026-02-18
Cumbo Alexander
director, officer: President and CEO
30,031 SH @ $0.00
2026-02-13
Hanrahan Jessie
officer: Chief Regulatory Officer
8,125 SH @ $0.00
2026-02-13
Hanrahan Jessie
officer: Chief Regulatory Officer
4,134 SH @ $5.82
2026-02-18